Timber Pharmaceuticals (TMBR) 10-Q 7 Dec 18 2019 Q3 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	9 Months Ended
	Oct. 31, 2018	Nov. 30, 2018
DOCUMENT AND ENTITY INFORMATION
Entity Registrant Name	BioPharmX Corp
Entity Central Index Key	1,504,167
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 31, 2018
Current Fiscal Year End Date	--01-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		212,815,296
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,019
Trading Symbol	BPMX

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 31, 2018	Jan. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,018	$ 7,576
Accounts receivable, net	4	7
Inventories	10	10
Prepaid expenses and other current assets	548	388
Total current assets	3,580	7,981
Property and equipment, net	135	109
Total assets	3,715	8,090
Current liabilities:
Accounts payable	1,387	1,376
Accrued expenses and other current liabilities	1,670	1,603
Total current liabilities	3,057	2,979
Long-term liabilities:
Long-term liabilities	67	39
Total liabilities	3,124	3,018
Commitments and contingencies (Note 5)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of October 31, 2018 and January 31, 2018
Common stock, $0.001 par value; 450,000,000 shares authorized; 191,648,630 and 160,062,509 shares issued and outstanding as of October 31, 2018 and January 31, 2018, respectively	192	160
Additional paid-in capital	74,877	66,190
Accumulated deficit	(74,478)	(61,278)
Total stockholders' equity	591	5,072
Total liabilities and stockholders' equity	$ 3,715	$ 8,090

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2018	Jan. 31, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000	10,000,000
Series A convertible preferred stock, shares issued	0	0
Series A convertible preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	191,648,630	160,062,509
Common stock, shares outstanding	191,648,630	160,062,509

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues, net	$ 10	$ 18	$ 52	$ 54
Cost of goods sold	60	8	80	28
Gross margin	(50)	10	(28)	26
Operating expenses:
Research and development	2,228	2,111	7,285	7,465
Sales and marketing	550	546	1,717	1,929
General and administrative	1,624	1,088	4,252	3,671
Total operating expenses	4,402	3,745	13,254	13,065
Loss from operations	(4,452)	(3,735)	(13,282)	(13,039)
Change in fair value of warrant liability	42	169	(1)	330
Other income and expense, net	20	(148)	83	(142)
Loss before provision for income taxes	(4,390)	(3,714)	(13,200)	(12,851)
Provision for income taxes			2	1
Net loss and comprehensive loss	$ (4,390)	$ (3,714)	$ (13,202)	$ (12,852)
Basic and diluted net loss per share	$ (0.02)	$ (0.05)	$ (0.07)	$ (0.17)
Shares used in computing basic and diluted net loss per share	191,360,000	79,659,000	187,551,000	73,977,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Cash flows from operating activities:
Net loss	$ (13,202)	$ (12,852)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,757	1,416
Expense related to modification of warrants		151
Depreciation expense	48	38
Change in fair value of warrant liability	1	(330)
Changes in assets and liabilities:
Accounts receivable	3	(4)
Inventories		23
Prepaid expenses and other assets	(160)	(289)
Accounts payable	11	(545)
Accrued expenses and other liabilities	49	528
Net cash used in operating activities	(11,493)	(11,864)
Cash flows from investing activities:
Purchases of property and equipment	(13)	(41)
Net cash used in investing activities	(13)	(41)
Cash flows from financing activities:
Proceeds from the issuance of common stock, preferred stock and warrants, net of issuance costs		6,355
Proceeds from exercises of common stock warrants	6,961	615
Proceeds from exercises of stock options	1	10
Payments on capital lease obligation	(14)
Net cash provided by financing activities	6,948	6,980
Net decrease in cash and cash equivalents	(4,558)	(4,925)
Cash and cash equivalents as of beginning of period	7,576	6,501
Cash and cash equivalents as of end of period	$ 3,018	$ 1,576

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Oct. 31, 2018
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business BioPharmX Corporation (the “Company”) is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. The Company has one wholly-owned subsidiary, BioPharmX, Inc., a Nevada corporation. The Company is a specialty pharmaceutical company focused on utilizing its proprietary drug delivery technologies to develop and commercialize novel prescription products that address large markets in dermatology. The Company’s objective is to develop products that treat health or age-related conditions that (1) are not presently being addressed or treated at all or (2) are currently treated with drug therapies or drug delivery approaches that are suboptimal. The Company’s strategy is designed to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Administration (FDA) approved active pharmaceutical ingredients and biological materials, while, in appropriate circumstances, reducing the time, cost and risk typically associated with new product development by repurposing drugs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. The Company believes these approaches may reduce drug development risk and could reduce the time and resources it spends during development. Its current platform technologies include innovative delivery mechanisms for antibiotics, biologic materials and molecular iodine (I 2 ). Since the Company’s inception, substantially all of the Company’s efforts have been devoted to developing its product candidates, including conducting preclinical and clinical trials, and providing general and administrative support for its operations. The Company has financed its operations primarily through the sale of equity and convertible notes. Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2018, filed on April 26, 2018. The condensed consolidated balance sheet as of January 31, 2018, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2018 and January 31, 2018, and the Company’s results of operations for the three and nine months ended October 31, 2018 and 2017 and its cash flows for the nine months ended October 31, 2018 and 2017. The results for the three and nine months ended October 31, 2018 are not necessarily indicative of the results to be expected for the year ending January 31, 2019 or any future period. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the standard cost method which approximates actual cost on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for inventory, which may have become obsolete or are in excess of anticipated demand or net realizable value. If future demand or market conditions for the products are less favorable than forecasted, the Company may be required to record additional write-downs, which would negatively affect its results of operations in the period when the write-downs were recorded. The Company must order components for its products and build inventory in advance of product shipments. The Company has a purchase commitment relating to the manufacturing of VI 2 OLET finished product (iodine supplement tablets) and is non-cancelable as detailed in Note 5. The Company assesses its purchase commitment based on demand forecasts and establishes a liability for quantities deemed in excess of these forecasts. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the three or nine months ended October 31, 2018. Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were approximately $5,000 and $4,000 for the three months ended October 31, 2018 and 2017, respectively, and approximately $9,000 and $23,000 for the nine months ended October 31, 2018 and 2017, respectively. Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2018 and 2017 excludes 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2018 and 2017, approximately 190,102,000 and 58,382,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive. Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss. Revenue Recognition Effective February 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method. The cumulative effect of the initial application of ASC 606 of approximately $2,000 was recognized as an adjustment to accumulated deficit and a decrease to deferred revenue as of February 1, 2018. The adoption of ASC 606 did not have a material impact on the Company’s condensed consolidated balance sheet, statement of operations and comprehensive loss for the three or nine months ended October 31, 2018 and statement of cash flows for the nine months ended October 31, 2018. Revenue recognized to date is from the sale of VI 2 OLET, an iodine dietary supplement. Revenue is recognized when control is transferred to the customer, which is typically upon shipment. There are no significant post-shipment obligations. Revenue is recognized at the transaction price, which includes estimates of variable consideration for reserves related to estimated product returns, pricing discounts or other concessions. These estimates are based on estimates of the amount earned or to be claimed on the related sales and are based on historical information and current contractual requirements. The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of October 31, 2018 or February 1, 2018. Separately, accounts receivable, net, represent receivables from contracts with customers. As of October 31, 2018 and February 1, 2018, deferred revenue was immaterial. The Company applies the practical expedient to make adjustments for a significant financing component unnecessary if, at contract inception, the Company does not expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed one year. During the three and nine months ended October 31, 2018, the Company did not have any contracts for the sale of its products with its customers with a significant financing component. The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. During the three and nine months ended October 31, 2018, the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was one year or less. Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Summary of Significant Accounting Policies These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the fiscal year ended January 31, 2018. There have been no significant changes in the Company’s significant accounting policies for the three and nine months ended October 31, 2018, except for the adoption of ASC 606 as discussed above, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended January 31, 2018. Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases , and in July 2018, Accounting Standards Update 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is in the process of evaluating the impact of adoption of this standard on its condensed consolidated financial statements. In June 2018, the FASB issued Accounting Standards Update 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption of this amendment on its condensed consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Oct. 31, 2018
GOING CONCERN
GOING CONCERN	2. GOING CONCERN The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and will continue to conduct operations for the foreseeable future and realize assets and discharge liabilities in the ordinary course of operations. As of October 31, 2018, the Company had cash and cash equivalents of $3.0 million and working capital of $0.5 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock and the issuance of convertible notes. The Company incurred a net loss of $4.4 million and $3.7 million for the three months ended October 31, 2018 and 2017, respectively, and a net loss of $13.2 million and $12.9 million for the nine months ended October 31, 2018 and 2017, respectively. The Company had an accumulated deficit of $74.5 million as of October 31, 2018. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company continues its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses and either entering into a strategic partnership or raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available or on terms which are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, enter into a strategic partnership or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Oct. 31, 2018
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. · Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. · Level 2— Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. · Level 3— Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. As of October 31, 2018 and January 31, 2018, the Company held $2.5 million and $7.1 million, respectively, in money market funds, which are classified as Level 1 within the fair value hierarchy. No unrealized gains or losses are recorded in connection with these amounts. The fair value of the warrant liability was classified as a Level 3 liability, as the Company uses unobservable inputs to value it. The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2018 $ 39 Change in fair value of warrants 66 Balance as of April 30, 2018 105 Change in fair value of warrants (23) Balance as of July 31, 2018 82 Change in fair value of warrants (42) Balance as of October 31, 2018 $ 40

BALANCE SHEET DETAILS

BALANCE SHEET DETAILS	9 Months Ended
	Oct. 31, 2018
BALANCE SHEET DETAILS
BALANCE SHEET DETAILS	4. BALANCE SHEET DETAILS October 31, January 31, 2018 2018 (in thousands) Inventories: Work in process $ $ 5 Finished goods 1 Channel inventory 4 $ $

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Oct. 31, 2018
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	5. COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company’s commitments as of October 31, 2018 (in thousands): Fiscal years ending January 31, Total 2019 2020 2021 2022 2023 Operating lease $ 1,331 $ $ 280 $ 314 $ 324 $ 334 Purchase commitment 807 — — Total $ 2,138 $ 348 $ $ $ $ On December 14, 2016, the Company signed a lease for 12,066 square feet of office and laboratory space in Menlo Park, California. In September 2017, the lease term was extended to December 2018 and the square footage increased to 12,203 square feet. On October 30, 2018, the Company signed a lease for 11,793 square feet of office and laboratory space in San Jose, California. The Company expects to move into its new headquarters in December 2018. The future minimum lease payments for this new lease are included in the table above. Rent expense for the three months ended October 31, 2018 and 2017 was approximately $160,000 and $154,000, respectively. Rent expense for the nine months ended October 31, 2018 and 2017 was approximately $480,000 and $453,000, respectively. The purchase commitment relates to the manufacturing of VI 2 OLET finished product (iodine supplement tablets) and is non-cancelable through the term of the contract. The Company assesses its purchase commitments based on demand forecasts and establishes a liability for quantities deemed in excess of these forecasts. In November 2018, the Company divested the rights to develop, manufacture, market and sale VI 2 OLET. The divestiture included the transfer of the fiscal year 2020 and 2021 purchase commitment obligations to the new owner. See Note 9 for further details. The Company is party to an agreement with a contract research organization (CRO) to conduct the Phase 2 clinical trial for BPX04, a topical antibiotic for the treatment of rosacea. The actual amounts owed under the agreement and the timing of those obligations depend on various factors, including the rate of patient enrollment, any protocol amendments and other factors relating to the clinical trial. As of October 31, 2018, the remaining liability under the agreement, excluding any potential amendments to the agreement, was $1.0 million. The Company can terminate the agreement at any time and any amounts incurred through the termination date would be due to the CRO. The Company recorded a capital lease obligation related to laboratory equipment in March 2018. The leased asset value was approximately $61,000 and the corresponding current and long-term liabilities were recorded in accrued liabilities and other current liabilities and long-term liabilities, respectively. Legal Proceedings The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patents or other intellectual property rights. The Company is not a party to any material legal proceeding, nor is it aware of any pending or threatened litigation that the Company believes is likely to have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has entered into indemnification agreements with its directors, officers and certain of its medical advisors that may require the Company to indemnify its directors, officers and such medical advisors against liabilities that may arise by reason of their status or service in these roles, other than liabilities arising from willful misconduct of the individual. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date. License Agreement In March 2013, the Company entered into an amended and restated collaboration and license agreement with Iogen LLC, which provides the Company with a license to certain rights to label, market, and resell the finished inventory and ongoing manufacturing of the Iogen molecular iodine technology for future product formulation development and commercialization. New formulation patents developed by the Company will be solely owned by the Company. The agreement gives the Company a perpetual, fully paid-up, exclusive license to make, have made, use, sell and offer for sale and import products. Pursuant to the terms of the license, the Company must pay: · a fee for the exclusive license to the IP. · 30% of net profit associated with direct commercialization of an over-the-counter product or 30% of net royalties received from any sub-licensee. · a royalty of 3% of net sales for the first 24 months of commercialization and 2% of net sales thereafter for a prescription iodine tablet developed and commercialized under the license. · a royalty of 3% of net sales for the first 12 months of commercialization for other products developed and commercialized under the license and 2% of net sales thereafter until expiration of applicable patents covering such products and 1% thereafter. · a fixed royalty fee for the protection and indemnification of licensed intellectual property right (IP rights) for the prescription product developed, marketed and sold from newly developed formulations as long as the patents are valid and cover the prescription product. · a fixed royalty fee for the protection and indemnification of licensed IP rights for the other products utilizing the molecular iodine technology developed, marketed and sold from newly developed formulations as long as the patents are valid and cover the prescription product. No royalties have been required to be accrued in accordance with the license agreement as of October 31, 2018.

CONVERTIBLE PREFERRED STOCK AND

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY	9 Months Ended
	Oct. 31, 2018
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY	6. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY Common Stock In April 2017, the Company issued 6,410,258 shares of common stock at a price per share of $0.78 resulting in net proceeds of $4.4 million and warrants to purchase 3,365,385 shares of common stock at an exercise price of $0.90 in a registered direct offering. In July 2017, the Company issued 5,500,000 shares of common stock at a price per share of $0.36 resulting in net proceeds of $1.9 million in a registered direct offering. In November 2017, the Company issued 45,275,000 shares of common stock, pre-funded warrants to purchase 28,225,000 shares of common stock, and accompanying Series A common warrants to purchase 73,500,000 shares of common stock (Series A Warrants), and accompanying Series B common warrants to purchase 73,500,000 shares of common stock (Series B Warrants), resulting in net proceeds of $9.7 million. Each share of common stock and pre-funded warrant was sold together with a Series A Warrant to purchase one share of common stock and a Series B Warrant to purchase one share of common stock. The public offering price was $0.15 per share of common stock and accompanying Series A Warrant and Series B Warrant and $0.1490 per pre-funded warrant and accompanying Series A Warrant and Series B Warrant. The pre-funded warrants were issued and sold to purchasers in lieu of shares of common stock that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or at the election of the purchaser, 9.99%) of the Company’s outstanding common stock immediately following the closing of the offering. The pre-funded warrants have a nominal exercise price of $0.001 per share and have been fully exercised. The Series A Warrants have an exercise price of $0.20 per share, are exercisable immediately and expire five years from the date of issuance. The Series B Warrants have an exercise price of $0.25 per share, are exercisable immediately and expire on the earlier of (1) the twenty-first trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its Phase 3 trials for BPX01, and (2) the eighteen month anniversary of issuance. Series A Convertible Preferred Stock Pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on November 22, 2016, 10,000 shares of Series A convertible preferred stock were designated. In November 2016, the Company issued 1,515 shares of Series A convertible preferred stock (Preferred Stock), which included warrants to purchase 3,246,429 shares of common stock. The Preferred Stock had a purchase price of $1,000 per share and was convertible into common stock at a conversion rate of $0.35 per share. The Preferred Stock contained a beneficial conversion feature valued at $0.1 million, which was recorded as a deemed dividend at the time of issuance, which was considered to be the earliest time of conversion. In January 2018, the Preferred Stock was converted into 4,328,571 shares of common stock. Pursuant to the Certificate of Elimination filed with the Secretary of State of the State of Delaware on March 6, 2018, all shares of Series A convertible preferred stock previously designated were returned to the status of authorized but unissued shares of preferred stock, without designation as to series or rights, preferences, privileges or limitations. Warrants In the first quarter of fiscal year 2019, the Company received $7.0 million from the exercise of warrants to purchase common stock. A summary of warrants outstanding warrants as of October 31, 2018 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 60,088,727 $ 0.25 May 2019 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2018, the fair value of the warrant liability was approximately $40,000 and was included in long-term liabilities. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the condensed consolidated statement of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with certain of these warrant holders to cash exercise up to 26,666,666 shares of common stock underlying the warrants at an exercise price per share of $0.14. See Note 9 for further details. Equity Incentive Plan On July 5, 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan), which permits the Company to grant equity awards to directors, officers, employees and consultants. In connection with the adoption of the 2016 Plan, the Company ceased to grant equity awards under its 2014 Equity Incentive Plan (2014 Plan), which was adopted on January 23, 2014. All grants and awards under the 2014 Plan, including stock options previously issued under BioPharmX, Inc.’s 2011 Equity Incentive Plan that were substituted with stock options issued under the 2014 Plan, remain in effect in accordance with their terms. Stock options generally vest in one to four years and expire ten years from the date of grant. In March 2017, the 2016 Plan was amended and the shares reserved for issuance were increased by 20,000,000 shares to a total of 24,000,000 shares of common stock. In August 2018, the 2016 Plan was amended and the shares reserved for issuance were increased by 50,000,000 shares to a total of 74,000,000 shares of common stock. The 2014 Plan and 2016 Plan are referred to collectively as the “Plans.” The following table summarizes the Company’s stock option awards under the Plans: Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2018 1,884,878 24,724,663 $ 0.41 9.17 $ 304 Exercised — (10,140) $ 0.13 Cancelled and expired under the 2014 Plan — $ 0.73 Cancelled under the 2016 Plan 376,969 (376,969) $ 0.35 Balance as of April 30, 2018 2,261,847 $ 0.41 8.91 $ 1,300 Exercised — $ 0.10 Cancelled and expired under the 2014 Plan — $ 0.95 Cancelled under the 2016 Plan 116,763 (116,763) $ 0.35 Balance as of July 31, 2018 2,378,610 $ 0.41 8.67 $ 982 Shares authorized for issuance — Granted (10,444,000) $ 0.21 Exercised — (262,500) $ 0.10 Cancelled and expired under the 2014 Plan — $ 0.91 Cancelled under the 2016 Plan $ 0.26 Balance as of October 31, 2018 $ 0.36 7.81 $ 507 Vested and exercisable $ 0.51 5.50 $ 234 Vested and expected to vest $ 0.37 7.72 $ 490 Inducement Grants The Company has also awarded inducement option grants to purchase common stock to new employees outside of the 2016 Plan as permitted under Section 711(a) of the NYSE American Company Guide. Such options vest at the rate of 25% of the shares on the first anniversary of the commencement of such employee’s employment with the Company, and then one forty-eighth (1/48) of the shares monthly thereafter subject to such employee’s continued service. The following table summarizes the Company’s inducement grant stock option awards: Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2018 660,000 $ $ — Granted 400,000 $ — $ — Balance as of April 30, 2018 and July 31, 2018 1,060,000 $ $ Cancelled (53,855) $ — $ — Balance as of October 31, 2018 1,006,145 $ $ — Vested and exercisable 487,395 $ $ — Vested and expected to vest 970,103 $ $ — The following table summarizes significant ranges of outstanding and exercisable options as of October 31, 2018: Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.09 $ $ $1.10 - $1.85 $ $ $1.86 - $3.00 $ 100,000 $ 3.00 $ $ The total intrinsic value of stock options exercised during the three and nine months ended October 31, 2018 was approximately $24,000 and $26,000, respectively. The total intrinsic value of stock options exercised during the nine months ended October 31, 2017 was approximately $4,000. There were no stock options exercised during the three months ended October 31, 2017.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Oct. 31, 2018
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION	7. STOCK-BASED COMPENSATION The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2018 2017 2018 2017 Research and development $ 166 $ 131 $ 525 $ 397 Sales and marketing 114 98 355 289 General and administrative 438 236 877 730 Total $ 718 $ 465 $ 1,757 $ 1,416 The Company estimates the fair value of stock options granted using the Black-Scholes pricing model. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. For employee grants, the fair value is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. As of October 31, 2018, total compensation costs related to unvested, but not yet recognized, stock-based awards was $3.0 million, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 2.71 years and will be adjusted for subsequent changes in estimated forfeitures. Valuation Assumptions During the nine months ended October 31, 2018, the grant date fair value of stock options granted was $0.12 per share. The following assumptions were used to calculate the estimated fair value of awards granted for the periods ended: For the three months ended For the nine months ended October 31, October 31, 2018 2018 2017 Expected volatility 78.8% - 91.0% 78.8% - 91.0% 95.5% - 96.8% Expected term in years 4.0 - 8.6 4.0 - 8.6 6.0 - 9.6 Risk-free interest rate 2.72% - 3.10% 2.72% - 3.10% 1.80% - 2.35% Expected dividend yield — — — Expected Term The expected term represents the period that the Company’s stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data. Expected Volatility The Company uses the historical volatility of the price of shares of common stock of selected public companies, including the Company’s stock price, in the biotechnology sector due to its limited trading history. Risk-Free Interest Rate The Company bases the risk-free interest rate used in the Black-Scholes pricing model upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model. Expected Dividend The Company has never paid dividends on its shares of common stock and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Oct. 31, 2018
INCOME TAXES
INCOME TAXES	8. INCOME TAXES The Company evaluates its ability to recover deferred tax assets, in full or in part, by considering all available positive and negative evidence, including past operating results and its forecast of future taxable income on a jurisdictional basis. The Company bases its estimate of current and deferred taxes on the tax laws and rates that are currently in effect in the appropriate jurisdiction. Changes in laws or rates may affect the tax provision as well as the amount of deferred tax assets or liabilities. Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carry-forwards in the event of an “ownership change,” as defined by the Internal Revenue Code. If there should be an ownership change, the Company’s ability to utilize its carry-forwards could be limited. As of October 31, 2018 and January 31, 2018, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. The 2010 to 2018 tax years remain open for examination by the federal and state authorities.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Oct. 31, 2018
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise up to 26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants), with such New Warrants to be issued on a share-for-share basis in an amount equal to the number of shares underlying Existing Warrants that are cash exercised by February 28, 2019. The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. On November 27, 2018, the Company entered into an asset purchase agreement to divest the rights to develop, manufacture, market and sell its molecular iodine technology, including the dietary supplement product, VI 2 OLET (Purchase Agreement). The Purchase Agreement includes the sale of all tangible and intangible assets related to VI 2 OLET, including but not limited to existing customer and vendor arrangements, in exchange for 3% royalty payments on net revenues exceeding $1.0 million. In addition, after January 1, 2020, the purchaser may be relieved of its obligations to pay royalties to the Company by making a lump-sum payment to the Company. Under the Purchase Agreement, the Company will remain liable for any liabilities incurred prior to December 31, 2018, with the purchaser assuming responsibility for all liabilities thereafter. The purchase commitment obligations relating to the manufacturing of VI 2 OLET finished product incurred after December 31, 2018 are included in the vendor arrangements assigned under the Purchase Agreement. Upon the effectiveness of the Purchase Agreement, each of the Company’s prior collaboration, license, colocation and supply agreements related to VI 2 OLET were terminated or will be assigned to the purchaser.

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Oct. 31, 2018
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended January 31, 2018, filed on April 26, 2018. The condensed consolidated balance sheet as of January 31, 2018, included herein, was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s statement of financial position as of October 31, 2018 and January 31, 2018, and the Company’s results of operations for the three and nine months ended October 31, 2018 and 2017 and its cash flows for the nine months ended October 31, 2018 and 2017. The results for the three and nine months ended October 31, 2018 are not necessarily indicative of the results to be expected for the year ending January 31, 2019 or any future period.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the standard cost method which approximates actual cost on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for inventory, which may have become obsolete or are in excess of anticipated demand or net realizable value. If future demand or market conditions for the products are less favorable than forecasted, the Company may be required to record additional write-downs, which would negatively affect its results of operations in the period when the write-downs were recorded. The Company must order components for its products and build inventory in advance of product shipments. The Company has a purchase commitment relating to the manufacturing of VI 2 OLET finished product (iodine supplement tablets) and is non-cancelable as detailed in Note 5. The Company assesses its purchase commitment based on demand forecasts and establishes a liability for quantities deemed in excess of these forecasts.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company did not identify any impairment losses for the three or nine months ended October 31, 2018.
Advertising Expenses	Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were approximately $5,000 and $4,000 for the three months ended October 31, 2018 and 2017, respectively, and approximately $9,000 and $23,000 for the nine months ended October 31, 2018 and 2017, respectively.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock outstanding during the period. The weighted-average shares outstanding for the three and nine months ended October 31, 2018 and 2017 excludes 193,333 shares of unvested restricted common stock. Diluted net loss per share attributable to common stockholders is calculated based on the weighted-average number of shares of the Company’s common stock outstanding and other dilutive securities outstanding during the period. As of October 31, 2018 and 2017, approximately 190,102,000 and 58,382,000 of potentially dilutive securities, respectively, were excluded from the computation of diluted net loss per share because their effect on net loss per share would be anti-dilutive.
Warrant Liability	Warrant Liability The Company accounts for certain of its warrants as derivative liabilities based on provisions relating to cash settlement options. The Company recorded a liability for the fair value of the warrants at the time of issuance, and at each reporting date the warrants are revalued to the instrument’s fair value. The fair value of the warrants are estimated using the Black-Scholes pricing model. This liability is subject to fair value re-measurement until the warrants are exercised or expired, and any change in fair value is recognized as other income or expense in the condensed consolidated statements of operations and comprehensive loss.
Revenue Recognition	Revenue Recognition Effective February 1, 2018, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method. The cumulative effect of the initial application of ASC 606 of approximately $2,000 was recognized as an adjustment to accumulated deficit and a decrease to deferred revenue as of February 1, 2018. The adoption of ASC 606 did not have a material impact on the Company’s condensed consolidated balance sheet, statement of operations and comprehensive loss for the three or nine months ended October 31, 2018 and statement of cash flows for the nine months ended October 31, 2018. Revenue recognized to date is from the sale of VI 2 OLET, an iodine dietary supplement. Revenue is recognized when control is transferred to the customer, which is typically upon shipment. There are no significant post-shipment obligations. Revenue is recognized at the transaction price, which includes estimates of variable consideration for reserves related to estimated product returns, pricing discounts or other concessions. These estimates are based on estimates of the amount earned or to be claimed on the related sales and are based on historical information and current contractual requirements. The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No such assets existed as of October 31, 2018 or February 1, 2018. Separately, accounts receivable, net, represent receivables from contracts with customers. As of October 31, 2018 and February 1, 2018, deferred revenue was immaterial. The Company applies the practical expedient to make adjustments for a significant financing component unnecessary if, at contract inception, the Company does not expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed one year. During the three and nine months ended October 31, 2018, the Company did not have any contracts for the sale of its products with its customers with a significant financing component. The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. During the three and nine months ended October 31, 2018, the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was one year or less. Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and notes thereto contained in the Annual Report on Form 10-K for the fiscal year ended January 31, 2018. There have been no significant changes in the Company’s significant accounting policies for the three and nine months ended October 31, 2018, except for the adoption of ASC 606 as discussed above, as compared to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended January 31, 2018.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases , and in July 2018, Accounting Standards Update 2018-11, Targeted Improvements , which requires entities to recognize assets and liabilities for leases with lease terms greater than twelve months. The new guidance also requires quantitative and qualitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is in the process of evaluating the impact of adoption of this standard on its condensed consolidated financial statements. In June 2018, the FASB issued Accounting Standards Update 2018-07, Improvements to Nonemployee Share-Based Payment Accounting , which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The amendment is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of adoption of this amendment on its condensed consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Oct. 31, 2018
FAIR VALUE MEASUREMENTS
Schedule of Fair Value of Warrant Liability Classified as Level 3 Liabilities	The table below presents the activity within Level 3 of the fair value hierarchy (in thousands): Warrant Liability Balance as of January 31, 2018 $ 39 Change in fair value of warrants 66 Balance as of April 30, 2018 105 Change in fair value of warrants (23) Balance as of July 31, 2018 82 Change in fair value of warrants (42) Balance as of October 31, 2018 $ 40

BALANCE SHEET DETAILS (Tables)

BALANCE SHEET DETAILS (Tables)	9 Months Ended
	Oct. 31, 2018
BALANCE SHEET DETAILS
Schedule of Inventories	October 31, January 31, 2018 2018 (in thousands) Inventories: Work in process $ $ 5 Finished goods 1 Channel inventory 4 $ $

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Oct. 31, 2018
COMMITMENTS AND CONTINGENCIES
Future minimum commitments	The following table summarizes the Company’s commitments as of October 31, 2018 (in thousands): Fiscal years ending January 31, Total 2019 2020 2021 2022 2023 Operating lease $ 1,331 $ $ 280 $ 314 $ 324 $ 334 Purchase commitment 807 — — Total $ 2,138 $ 348 $ $ $ $

CONVERTIBLE PREFERRED STOCK A_2

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Oct. 31, 2018
Schedule of outstanding warrants	In the first quarter of fiscal year 2019, the Company received $7.0 million from the exercise of warrants to purchase common stock. A summary of warrants outstanding warrants as of October 31, 2018 is as follows: Total Price per Share Expiration Date Warrants related to January 2014 agreement 289,505 $ 1.85 May 2019 Warrants related to May 2014 agreement 316,395 $2.035 May 2019 Warrants related to April to November 2014 financing 1,661,055 $ 3.70 April 2019 - November 2019 Warrants related to June 2015 financing 109,091 $ 2.75 June 2020 Warrants related to April 2016 financing 1,952,000 $ 1.20 April 2021 Warrants related to September 2016 financing (1) 1,286,501 $ 0.75 September 2021 to March 2022 Warrants related to November 2016 financing 30,406,061 $ 0.35 November 2022 to November 2024 Warrants related to November 2016 financing 895,450 $ 0.44 November 2022 Warrants related to November 2016 financing 198,214 $ 0.33 November 2022 Warrants related to April 2017 financing 801,282 $ 0.90 October 2022 Warrants related to October 2017 financing (2) 3,846,152 $ 0.30 October 2022 Warrants related to November 2017 financing 56,935,191 $ 0.20 November 2022 Warrants related to November 2017 financing (3) 60,088,727 $ 0.25 May 2019 (1) In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of October 31, 2018, the fair value of the warrant liability was approximately $40,000 and was included in long-term liabilities. (2) On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the condensed consolidated statement of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30. (3) On November 20, 2018, the Company entered into agreements with certain of these warrant holders to cash exercise up to 26,666,666 shares of common stock underlying the warrants at an exercise price per share of $0.14. See Note 9 for further details.
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Vested and Exercisable Weighted Average Weighted Weighted Remaining Average Number Average Number Contractual Exercise Vested and Exercise Range of Exercise Prices Outstanding Life (in Years) Prices Exercisable Prices $0.10 - $0.16 $ $ $0.17 - $0.35 $ $ $0.36 - $0.65 $ $ $0.66 - $1.09 $ $ $1.10 - $1.85 $ $ $1.86 - $3.00 $ 100,000 $ 3.00 $ $
2014 Equity Incentive Plan
Stock option plan activity	Weighted Average Remaining Aggregate Available for Exercise Contractual Intrinsic Grant Shares Prices Life Value (in thousands) Balance as of February 1, 2018 1,884,878 24,724,663 $ 0.41 9.17 $ 304 Exercised — (10,140) $ 0.13 Cancelled and expired under the 2014 Plan — $ 0.73 Cancelled under the 2016 Plan 376,969 (376,969) $ 0.35 Balance as of April 30, 2018 2,261,847 $ 0.41 8.91 $ 1,300 Exercised — $ 0.10 Cancelled and expired under the 2014 Plan — $ 0.95 Cancelled under the 2016 Plan 116,763 (116,763) $ 0.35 Balance as of July 31, 2018 2,378,610 $ 0.41 8.67 $ 982 Shares authorized for issuance — Granted (10,444,000) $ 0.21 Exercised — (262,500) $ 0.10 Cancelled and expired under the 2014 Plan — $ 0.91 Cancelled under the 2016 Plan $ 0.26 Balance as of October 31, 2018 $ 0.36 7.81 $ 507 Vested and exercisable $ 0.51 5.50 $ 234 Vested and expected to vest $ 0.37 7.72 $ 490
Outside of the 2016 Equity Incentive Plan
Stock option plan activity	Weighted Average Remaining Exercise Contractual Aggregate Shares Prices Life Intrinsic Value (in thousands) Balance as of February 1, 2018 660,000 $ $ — Granted 400,000 $ — $ — Balance as of April 30, 2018 and July 31, 2018 1,060,000 $ $ Cancelled (53,855) $ — $ — Balance as of October 31, 2018 1,006,145 $ $ — Vested and exercisable 487,395 $ $ — Vested and expected to vest 970,103 $ $ —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Oct. 31, 2018
STOCK-BASED COMPENSATION
Summary of stock based compensation expense	The following table summarizes the stock-based compensation expenses included in the condensed consolidated statement of operations and comprehensive loss (in thousands): For the three months ended For the nine months ended October 31, October 31, 2018 2017 2018 2017 Research and development $ 166 $ 131 $ 525 $ 397 Sales and marketing 114 98 355 289 General and administrative 438 236 877 730 Total $ 718 $ 465 $ 1,757 $ 1,416
Black-Scholes option pricing model fair value assumptions	For the three months ended For the nine months ended October 31, October 31, 2018 2018 2017 Expected volatility 78.8% - 91.0% 78.8% - 91.0% 95.5% - 96.8% Expected term in years 4.0 - 8.6 4.0 - 8.6 6.0 - 9.6 Risk-free interest rate 2.72% - 3.10% 2.72% - 3.10% 1.80% - 2.35% Expected dividend yield — — —

DESCRIPTION OF BUSINESS AND S_3

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Assets and Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Advertising Expenses
Advertising expenses	$ 5,000	$ 4,000	$ 9,000	$ 23,000

DESCRIPTION OF BUSINESS AND S_4

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Net Loss Per Share
Common stock shares expected to vest			193,333	193,333	193,333	193,333
Potentially dilutive securities excluded from computation of diluted loss per share	190,102,000	58,382,000

DESCRIPTION OF BUSINESS AND S_5

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details) - ASU 2014-09 - ASC 606 Adjustment	Feb. 01, 2018USD ($)
Revenue Recognition
Accumulated deficit adjustment	$ 2,000
Deferred revenue decrease	$ 2,000

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
GOING CONCERN
Cash and cash equivalents	$ 3,018	$ 1,576	$ 3,018	$ 1,576	$ 7,576	$ 6,501
Working capital	500		500
Net loss	4,390	$ 3,714	13,200	$ 12,851
Accumulated deficit	$ 74,478		$ 74,478		$ 61,278

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Money Market Funds - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Oct. 31, 2018	Jan. 31, 2018
Fair Value Measurements
Unrealized gains (losses)	$ 0	$ 0
Level 1
Fair Value Measurements
Available-for-sale securities	$ 2.5	$ 7.1

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value of Warrant Liability Classified as Level 3 Liabilities (Details) - Level 3 - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018
Fair Value of Warrant Liability Classified as Level 3 Liabilities
Beginning balance	$ 82	$ 105	$ 39
Change in fair value of warrants	(42)	(23)	66
Ending balance	$ 40	$ 82	$ 105

BALANCE SHEET DETAILS (Details)

BALANCE SHEET DETAILS (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Jan. 31, 2018
Inventories:
Work in process	$ 4	$ 5
Finished goods	4	1
Channel inventory	2	4
Total	$ 10	$ 10

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Commitments (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2018USD ($)	Oct. 31, 2018USD ($)ft²	Oct. 31, 2017USD ($)	Oct. 31, 2018USD ($)ft²	Oct. 31, 2017USD ($)	Sep. 30, 2017ft²	Dec. 14, 2016ft²
Operating lease commitments
2,019		$ 79,000		$ 79,000
2,020		280,000		280,000
2,021		314,000		314,000
2,022		324,000		324,000
2,023		334,000		334,000
Total		1,331,000		1,331,000
Purchase commitments
2,019		269,000		269,000
2,020		269,000		269,000
2,021		269,000		269,000
Total		807,000		807,000
Contractual obligation commitments
2,019		348,000		348,000
2,020		549,000		549,000
2,021		583,000		583,000
2,022		324,000		324,000
2,023		334,000		334,000
Total		2,138,000		2,138,000
Rent expense
Rent expense		160,000	$ 154,000	480,000	$ 453,000
Capital lease obligation	$ 61,000
CRO agreements, remaining cost		$ 1,000,000		$ 1,000,000
Menlo Park, California
Rent expense
Leased office and laboratory area | ft²						12,203	12,066
San Jose, California
Rent expense
Leased office and laboratory area | ft²		11,793		11,793

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Legal Proceedings and License Agreement (Details)	9 Months Ended
	Oct. 31, 2018USD ($)
License Agreement
Estimated claim liability	$ 0
Royalties accrued	$ 0
License Agreement | Iogen, LLC.
License Agreement
Non Royalty license fee equal to a certain percentage of net profit associated with OTC product	30.00%
Non Royalty license fee equal to a certain percentage of net royalties received from any sub-licensee	30.00%
License Agreement | Prescription Iodine Tablet | Iogen, LLC.
License Agreement
Royalty fee percentage based on net sales over a specific time period of commercialization	3.00%
Royalty fee percentage based on net sales after a specific period of time	2.00%
Time period for determining initial royalty fee as a percent of net sales	24 months
License Agreement | Other Products | Iogen, LLC.
License Agreement
Royalty fee percentage based on net sales over a specific time period of commercialization	3.00%
Royalty fee percentage based on net sales from initial period until expiration of applicable patents	2.00%
Royalty fee percentage based on net sales after a specific period of time	1.00%
Time period for determining initial royalty fee as a percent of net sales	12 months

CONVERTIBLE PREFERRED STOCK A_3

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Nov. 30, 2017	Jul. 31, 2017	Apr. 30, 2017
Beneficial ownership interest if common stock issued (as a percentage)	9.99%
Minimum
Beneficial ownership interest if common stock issued (as a percentage)	4.99%
Common Stock
Issuance of stock (in shares)	45,275,000
Warrant
Net proceeds from issuance of common stock and warrants	$ 9.7
Prefunded warrants
Warrants exercise price (in dollars per share)	$ 0.001
Prefunded warrants | Warrant
Number of shares of common stock subject to warrant (in shares)	28,225,000
Series A Warrants | Warrant
Number of shares of common stock subject to warrant (in shares)	73,500,000
Warrants exercise price (in dollars per share)	$ 0.20
Warrants, expiration term	5 years
Series B Warrants | Warrant
Number of shares of common stock subject to warrant (in shares)	73,500,000
Warrants exercise price (in dollars per share)	$ 0.25
Warrants exercisable after number of trading days from a press release	20 days
Warrants exercisable after number of months from issuance	18 months
Prefunded warrants and series A | Common Stock
Number of common shares called by each warrant (in shares)	1
Prefunded warrants and series B | Common Stock
Number of common shares called by each warrant (in shares)	1
Prefunded warrants, series A and series B | Warrant
Warrants exercise price (in dollars per share)	$ 0.1490
Series A and series B | Common Stock
Warrants exercise price (in dollars per share)	$ 0.15
Private placement
Issuance of stock (in shares)		5,500,000	6,410,258
Net proceeds from the sale of common stock		$ 1.9	$ 4.4
Share price (in dollars per share)		$ 0.36	$ 0.78
Number of shares of common stock subject to warrant (in shares)			3,365,385
Warrants exercise price (in dollars per share)			$ 0.90

CONVERTIBLE PREFERRED STOCK A_4

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - Preferred Stock & Warrants (Details)	Oct. 23, 2017USD ($)item$ / sharesshares	Nov. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)item$ / sharesshares	Oct. 31, 2018USD ($)$ / sharesshares	Oct. 31, 2017USD ($)	Nov. 20, 2018$ / sharesshares	Jan. 31, 2018shares	Jul. 31, 2017$ / shares	Apr. 30, 2017$ / sharesshares
Equity
Series A convertible preferred stock, shares authorized				10,000,000			10,000,000
Series A convertible preferred stock, shares issued				0			0
Proceeds from exercises of common stock warrants | $				$ 6,961,000	$ 615,000
Private placement
Equity
Share price (in dollars per share) | $ / shares								$ 0.36	$ 0.78
Warrants exercise price (in dollars per share) | $ / shares									$ 0.90
Number of shares of common stock subject to warrant (in shares)									3,365,385
Warrant | Public Offering
Equity
Warrants exercise price (in dollars per share) | $ / shares		$ 0.35
Number of shares of common stock subject to warrant (in shares)		3,246,429
Warrants related to January 2014 agreement | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 1.85
Warrants outstanding				289,505
Warrants related to May 2014 agreement | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 2.035
Warrants outstanding				316,395
Warrants related to April to November 2014 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 3.70
Warrants outstanding				1,661,055
Warrants related to June 2015 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 2.75
Warrants outstanding				109,091
Warrants related to April 2016 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 1.20
Warrants outstanding				1,952,000
Warrants related to September 2016 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares			$ 0.75	$ 0.75
Warrant liability | $			$ 566,000	$ 40,000
Number of shares of common stock subject to warrant (in shares)			1,286,501
Warrants outstanding				1,286,501
Warrants related to September 2016 financing | Warrant | Risk-free interest rate
Equity
Warrants, measurement input | item			1.1
Warrants related to September 2016 financing | Warrant | Contractual term
Equity
Warrants, contractual term			5 years
Warrants related to September 2016 financing | Warrant | Expected volatility
Equity
Warrants, measurement input | item			95.8
Warrants related to September 2016 financing | Warrant | Dividend rate
Equity
Warrants, measurement input | item			0
Warrants related to November 2016 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.35
Warrants outstanding				30,406,061
Warrants related to November 2016 financing, tranche two | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.44
Warrants outstanding				895,450
Warrants related to November 2016 financing, tranche three | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.33
Warrants outstanding				198,214
Warrants related to April 2017 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.90
Warrants outstanding				801,282
Warrants related to October 2017 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares	$ 0.24			$ 0.30
Number of shares of common stock subject to warrant (in shares)	2,564,103
Warrants outstanding				3,846,152
Incremental fair value of warrants | $	$ 151,000
Warrants related to October 2017 financing | Warrant | Risk-free interest rate
Equity
Warrants, measurement input	2.03
Warrants related to October 2017 financing | Warrant | Contractual term
Equity
Warrants, contractual term	5 years
Warrants related to October 2017 financing | Warrant | Expected volatility
Equity
Warrants, measurement input	83.9
Warrants related to October 2017 financing | Warrant | Dividend rate
Equity
Warrants, measurement input | item	0
Warrants related to November 2017 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.20
Warrants outstanding				56,935,191
Warrants related to November 2017 financing, tranche two | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares				$ 0.25		$ 0.14
Warrants outstanding				60,088,727
Warrants related to November 2017 financing, tranche two | Warrant | Maximum
Equity
Number of shares of common stock subject to warrant (in shares)						26,666,666
Common Stock | Warrants related to October 2017 financing | Warrant
Equity
Warrants exercise price (in dollars per share) | $ / shares	$ 0.30
Warrants outstanding	3,846,152
Series A Convertible Preferred Stock
Equity
Series A convertible preferred stock, shares authorized		10,000
Series A convertible preferred stock, shares issued		1,515
Deemed dividend related to the beneficial conversion feature | $		$ 100,000
Number of common shares into which a share is convertible							4,328,571
Series A Convertible Preferred Stock | Public Offering
Equity
Share price (in dollars per share) | $ / shares		$ 1,000

CONVERTIBLE PREFERRED STOCK A_5

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - Equity Incentive Plan (Details) - 2016 Equity Incentive Plan - shares	1 Months Ended		9 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Additional shares authorized	50,000,000	20,000,000
Number of shares reserved for issuance	74,000,000	24,000,000
Options
Share-based Compensation Arrangement by Share-based Payment Award
Expiration period			10 years
Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			1 year
Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period			4 years

CONVERTIBLE PREFERRED STOCK A_6

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - Stock Option Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended				6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2018	Mar. 31, 2017	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2017	Jul. 31, 2018	Oct. 31, 2018	Jan. 31, 2018
Shares
Exercised						0
Plans
Available for Grant
Available for grant, beginning	2,378,610		2,378,610	2,261,847	1,884,878		1,884,878	1,884,878
Shares authorized for issuance			50,000,000
Granted			(10,444,000)
Available for grant, ending			46,018,197	2,378,610	2,261,847		2,378,610	46,018,197	1,884,878
Shares
Outstanding, Beginning	24,092,297		24,092,297	24,263,804	24,724,663		24,724,663	24,724,663
Granted			10,444,000
Exercised			(262,500)	(5,556)	(10,140)
Outstanding, Ending			30,116,501	24,092,297	24,263,804		24,092,297	30,116,501	24,724,663
Vested and exercisable			12,149,662					12,149,662
Vested and expected to vest			28,583,682					28,583,682
Weighted Average Exercise Prices
Outstanding, Beginning	$ 0.41		$ 0.41	$ 0.41	$ 0.41		$ 0.41	$ 0.41
Granted			0.21
Exercised			0.10	0.10	0.13
Outstanding, Ending			$ 0.36	$ 0.41	$ 0.41		$ 0.41	0.36	$ 0.41
Granted			10,444,000
Vested and exercisable			$ 0.51					0.51
Vested and expected to vest			$ 0.37					$ 0.37
Remaining Contractual Life
Outstanding			7 years 9 months 22 days	8 years 8 months 1 day	8 years 10 months 28 days				9 years 2 months 1 day
Vested and exercisable			5 years 6 months
Vested and expected to vest			7 years 8 months 19 days
Aggregate Intrinsic Value
Outstanding			$ 507	$ 982	$ 1,300		$ 982	$ 507	$ 304
Vested and exercisable			234					234
Vested and expected to vest			$ 490					$ 490
2014 Equity Incentive Plan
Available for Grant
Cancelled			73,709	49,188	73,750
Shares
Cancelled			(73,709)	(49,188)	(73,750)
Weighted Average Exercise Prices
Cancelled			$ 0.91	$ 0.95	$ 0.73
2016 Equity Incentive Plan
Available for Grant
Shares authorized for issuance	50,000,000	20,000,000
Cancelled			4,083,587	116,763	376,969
Shares
Cancelled			(4,083,587)	(116,763)	(376,969)
Weighted Average Exercise Prices
Cancelled			$ 0.26	$ 0.35	$ 0.35
Outside of the 2016 Equity Incentive Plan
Available for Grant
Granted							(400,000)
Cancelled			53,855
Shares
Outstanding, Beginning	1,060,000		1,060,000		660,000		660,000	660,000
Granted							400,000
Cancelled			(53,855)
Outstanding, Ending			1,006,145	1,060,000			1,060,000	1,006,145	660,000
Vested and exercisable			487,395					487,395
Vested and expected to vest			970,103					970,103
Weighted Average Exercise Prices
Outstanding, Beginning	$ 0.97		$ 0.97		$ 1.44		$ 1.44	$ 1.44
Granted							0.19
Cancelled			1.67
Outstanding, Ending			0.93	$ 0.97			$ 0.97	0.93	$ 1.44
Granted							400,000
Vested and exercisable			1.44					1.44
Vested and expected to vest			$ 0.95					$ 0.95
Remaining Contractual Life
Outstanding			6 years 8 months 1 day				8 years 1 month 2 days		7 years 8 months 19 days
Vested and exercisable								4 years 5 months 12 days
Vested and expected to vest								6 years 7 months 2 days
Aggregate Intrinsic Value
Outstanding				$ 4			$ 4
Outside of the 2016 Equity Incentive Plan | First anniversary
Available for Grant
Vesting percentage									25.00%
Outside of the 2016 Equity Incentive Plan | Subsequent to first anniversary
Available for Grant
Vesting percentage									2.083%

CONVERTIBLE PREFERRED STOCK A_7

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY - Range of Exercise Price (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Options Outstanding
Number Outstanding (in shares)	31,122,646		31,122,646
Weighted Average Remaining Contractual Life			7 years 9 months 11 days
Weighted Average Exercise Prices (in dollars per share)	$ 0.38		$ 0.38
Options Exercisable
Number Vested and Exercisable (in shares)	12,637,057		12,637,057
Weighted Average Exercise Prices (in dollars per share)	$ 0.55		$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Total intrinsic value of options exercised	$ 24,000		$ 26,000	$ 4,000
Exercised		0
$0.10 - $0.16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			$ 0.10
Exercise prices, high end of range (in dollars per share)			$ 0.16
Options Outstanding
Number Outstanding (in shares)	8,249,863		8,249,863
Weighted Average Remaining Contractual Life			7 years 8 months 9 days
Weighted Average Exercise Prices (in dollars per share)	$ 0.11		$ 0.11
Options Exercisable
Number Vested and Exercisable (in shares)	3,541,540		3,541,540
Weighted Average Exercise Prices (in dollars per share)	$ 0.10		$ 0.10
$0.17 - $0.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			0.17
Exercise prices, high end of range (in dollars per share)			$ 0.35
Options Outstanding
Number Outstanding (in shares)	12,965,729		12,965,729
Weighted Average Remaining Contractual Life			9 years
Weighted Average Exercise Prices (in dollars per share)	$ 0.22		$ 0.22
Options Exercisable
Number Vested and Exercisable (in shares)	2,214,574		2,214,574
Weighted Average Exercise Prices (in dollars per share)	$ 0.23		$ 0.23
$0.36 - $0.65
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			0.36
Exercise prices, high end of range (in dollars per share)			$ 0.65
Options Outstanding
Number Outstanding (in shares)	3,810,189		3,810,189
Weighted Average Remaining Contractual Life			5 years 11 months 16 days
Weighted Average Exercise Prices (in dollars per share)	$ 0.53		$ 0.53
Options Exercisable
Number Vested and Exercisable (in shares)	2,737,123		2,737,123
Weighted Average Exercise Prices (in dollars per share)	$ 0.54		$ 0.54
$0.66 - $1.09
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			0.66
Exercise prices, high end of range (in dollars per share)			$ 1.09
Options Outstanding
Number Outstanding (in shares)	4,595,720		4,595,720
Weighted Average Remaining Contractual Life			6 years 8 months 16 days
Weighted Average Exercise Prices (in dollars per share)	$ 0.77		$ 0.77
Options Exercisable
Number Vested and Exercisable (in shares)	2,800,095		2,800,095
Weighted Average Exercise Prices (in dollars per share)	$ 0.78		$ 0.78
$1.10 - $1.85
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			1.10
Exercise prices, high end of range (in dollars per share)			$ 1.85
Options Outstanding
Number Outstanding (in shares)	1,401,145		1,401,145
Weighted Average Remaining Contractual Life			5 years 5 months 19 days
Weighted Average Exercise Prices (in dollars per share)	$ 1.68		$ 1.68
Options Exercisable
Number Vested and Exercisable (in shares)	1,243,725		1,243,725
Weighted Average Exercise Prices (in dollars per share)	$ 1.69		$ 1.69
$1.86 - $3.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Exercise prices, low end of range (in dollars per share)			1.86
Exercise prices, high end of range (in dollars per share)			$ 3
Options Outstanding
Number Outstanding (in shares)	100,000		100,000
Weighted Average Remaining Contractual Life			6 years 6 months
Weighted Average Exercise Prices (in dollars per share)	$ 3		$ 3
Options Exercisable
Number Vested and Exercisable (in shares)	100,000		100,000
Weighted Average Exercise Prices (in dollars per share)	$ 3		$ 3

STOCK-BASED COMPENSATION - Expe

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Share-based Compensation
Stock-based compensation expense	$ 718	$ 465	$ 1,757	$ 1,416
Total compensation costs not yet recognized	3,000		$ 3,000
Average remaining amortization period for recognition of expense			2 years 8 months 16 days
Research and development
Share-based Compensation
Stock-based compensation expense	166	131	$ 525	397
Sales and marketing
Share-based Compensation
Stock-based compensation expense	114	98	355	289
General and administrative
Share-based Compensation
Stock-based compensation expense	$ 438	$ 236	$ 877	$ 730

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions (Details) - $ / shares	3 Months Ended	9 Months Ended
	Oct. 31, 2018	Oct. 31, 2018	Oct. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award
Grant date fair value of stock options granted		$ 0.12
Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	78.80%	78.80%	95.50%
Expected term in years	4 years	4 years	6 years
Risk-free interest rate	2.72%	2.72%	1.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Expected volatility	91.00%	91.00%	96.80%
Expected term in years	8 years 7 months 6 days	8 years 7 months 6 days	9 years 7 months 6 days
Risk-free interest rate	3.10%	3.10%	2.35%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Oct. 31, 2018	Jan. 31, 2018
INCOME TAXES
Liability for unrecognized tax benefits	$ 0	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	Nov. 27, 2018	Nov. 20, 2018	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
SUBSEQUENT EVENTS
Revenues, net			$ 10	$ 18	$ 52	$ 54
Warrant | Series B Warrants
SUBSEQUENT EVENTS
Warrants exercise price (in dollars per share)		$ 0.25
Subsequent Event | Prescription Iodine Tablet | License Agreement
SUBSEQUENT EVENTS
Royalty fee percentage based on net sales	3.00%
Subsequent Event | Minimum | License Agreement
SUBSEQUENT EVENTS
Revenues, net	$ 1,000
Subsequent Event | Warrant | Series B Warrants
SUBSEQUENT EVENTS
Warrants exercise price (in dollars per share)		$ 0.14
Subsequent Event | Warrant | Series B Warrants | Maximum
SUBSEQUENT EVENTS
Number of warrants exercised during period		26,666,666
Subsequent Event | Warrant | New Warrants
SUBSEQUENT EVENTS
Warrants exercise price (in dollars per share)		$ 0.164
Warrants expiry after number of months from issuance		30 months
Warrants exercisable period after anniversary of issuance (in months)		6 months
Subsequent Event | Warrant | New Warrants | Maximum
SUBSEQUENT EVENTS
Number of shares of common stock subject to warrant (in shares)		26,666,666